Pipeline
Candidate | PreclinicalPre | Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 |
---|---|---|---|---|
Hematology | ||||
Hematology | PreclinicalPre | Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 |
KER-050* Therapeutic Protein | ||||
KER-050* Therapeutic Protein | ||||
Pulmonary & Cardiovascular | ||||
Pulmonary & Cardiovascular | PreclinicalPre | Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 |
KER-012 Therapeutic Protein | ||||
KER-012 Therapeutic Protein | KER-012 Therapeutic Protein Chronic Heart Failure with Preserved Ejection Fraction/Reduced Ejection Fraction | |||
Neuromuscular | ||||
Neuromuscular | PreclinicalPre | Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 |
KER-065 Therapeutic Protein | KER-065 Therapeutic Protein | |||
Preclinical | ||||
Preclinical | PreclinicalPre | Phase 1Ph1 | Phase 2Ph2 | Phase 3Ph3 |
Musculoskeletal | Musculoskeletal | |||
Undisclosed Asssets | Undisclosed Asssets |
* Keros Therapeutics has granted an exclusive license to Hansoh (Shanghai) Healthtech Company Limited to develop, manufacture and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau. Keros Therapeutics exclusively owns rights to all other territories.
** Keros Therapeutics has exclusively licensed from The General Hospital Corporation rights in one patent family related to novel ALK2 inhibitors (KER-047).